GT Biopharma (GTBP) Competitors

$0.43 +0.01 (+3.27%)

Closing price 05/21/2026 04:00 PM Eastern

Extended Trading

$0.44 +0.00 (+0.46%)

As of 05/21/2026 07:53 PM Eastern

GTBP vs. ELUT, IXHL, INCR, NBRV, and ATOS

Should you buy GT Biopharma stock or one of its competitors? MarketBeat compares GT Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GT Biopharma include Elutia (ELUT), Incannex Healthcare (IXHL), InterCure (INCR), Nabriva Therapeutics (NBRV), and Atossa Genetics (ATOS). These companies are all part of the "pharmaceutical products" industry.

How does GT Biopharma compare to Elutia?

Elutia (NASDAQ:ELUT) and GT Biopharma (NASDAQ:GTBP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Elutia has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market.

Elutia has higher revenue and earnings than GT Biopharma. GT Biopharma is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$12.29M	4.18	$53.38M	$0.86	1.40
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A

In the previous week, Elutia had 1 more articles in the media than GT Biopharma. MarketBeat recorded 4 mentions for Elutia and 3 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 0.00 beat Elutia's score of -0.33 indicating that GT Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elutia	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GT Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

74.0% of Elutia shares are held by institutional investors. Comparatively, 8.2% of GT Biopharma shares are held by institutional investors. 27.6% of Elutia shares are held by insiders. Comparatively, 3.4% of GT Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Elutia has a net margin of 312.09% compared to GT Biopharma's net margin of 0.00%.

Company	Net Margins	Return on Equity	Return on Assets
Elutia	312.09%	N/A	-53.97%
GT Biopharma	N/A	N/A	-102.03%

Elutia presently has a consensus price target of $6.00, indicating a potential upside of 400.00%. Given Elutia's stronger consensus rating and higher possible upside, analysts clearly believe Elutia is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Elutia beats GT Biopharma on 13 of the 14 factors compared between the two stocks.

How does GT Biopharma compare to Incannex Healthcare?

Incannex Healthcare (NASDAQ:IXHL) and GT Biopharma (NASDAQ:GTBP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

GT Biopharma has lower revenue, but higher earnings than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	484.12	-$46.88M	-$8.41	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A

GT Biopharma's return on equity of 0.00% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
GT Biopharma	N/A	N/A	-102.03%

In the previous week, GT Biopharma had 2 more articles in the media than Incannex Healthcare. MarketBeat recorded 3 mentions for GT Biopharma and 1 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 1.11 beat GT Biopharma's score of 0.00 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Incannex Healthcare	Positive
GT Biopharma	Neutral

0.4% of Incannex Healthcare shares are held by institutional investors. Comparatively, 8.2% of GT Biopharma shares are held by institutional investors. 1.3% of Incannex Healthcare shares are held by company insiders. Comparatively, 3.4% of GT Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Incannex Healthcare has a beta of 7.22, indicating that its share price is 622% more volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

GT Biopharma beats Incannex Healthcare on 7 of the 11 factors compared between the two stocks.

How does GT Biopharma compare to InterCure?

GT Biopharma (NASDAQ:GTBP) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

GT Biopharma has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, InterCure has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

In the previous week, GT Biopharma had 3 more articles in the media than InterCure. MarketBeat recorded 3 mentions for GT Biopharma and 0 mentions for InterCure. GT Biopharma's average media sentiment score of 0.00 beat InterCure's score of 0.00 indicating that GT Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
GT Biopharma	Neutral
InterCure	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

8.2% of GT Biopharma shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 3.4% of GT Biopharma shares are owned by insiders. Comparatively, 0.2% of InterCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	N/A	-102.03%
InterCure	N/A	N/A	N/A

InterCure has higher revenue and earnings than GT Biopharma. GT Biopharma is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A
InterCure	$78.47M	0.59	-$10.37M	$0.03	28.22

Summary

InterCure beats GT Biopharma on 7 of the 10 factors compared between the two stocks.

How does GT Biopharma compare to Nabriva Therapeutics?

Nabriva Therapeutics (NASDAQ:NBRV) and GT Biopharma (NASDAQ:GTBP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

0.3% of Nabriva Therapeutics shares are held by institutional investors. Comparatively, 8.2% of GT Biopharma shares are held by institutional investors. 1.6% of Nabriva Therapeutics shares are held by insiders. Comparatively, 3.4% of GT Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nabriva Therapeutics has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

GT Biopharma has lower revenue, but higher earnings than Nabriva Therapeutics. GT Biopharma is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A

GT Biopharma has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. GT Biopharma's return on equity of 0.00% beat Nabriva Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%
GT Biopharma	N/A	N/A	-102.03%

In the previous week, GT Biopharma had 2 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 3 mentions for GT Biopharma and 1 mentions for Nabriva Therapeutics. GT Biopharma's average media sentiment score of 0.00 beat Nabriva Therapeutics' score of 0.00 indicating that GT Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nabriva Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GT Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Given Nabriva Therapeutics' higher probable upside, analysts plainly believe Nabriva Therapeutics is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nabriva Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

GT Biopharma beats Nabriva Therapeutics on 10 of the 14 factors compared between the two stocks.

How does GT Biopharma compare to Atossa Genetics?

GT Biopharma (NASDAQ:GTBP) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

Atossa Genetics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A

Atossa Genetics has a consensus price target of $36.33, indicating a potential upside of 631.05%. Given Atossa Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Atossa Genetics is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40

GT Biopharma has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market.

8.2% of GT Biopharma shares are owned by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are owned by institutional investors. 3.4% of GT Biopharma shares are owned by company insiders. Comparatively, 9.8% of Atossa Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

GT Biopharma's return on equity of 0.00% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	N/A	-102.03%
Atossa Genetics	N/A	-84.91%	-72.36%

In the previous week, Atossa Genetics had 5 more articles in the media than GT Biopharma. MarketBeat recorded 8 mentions for Atossa Genetics and 3 mentions for GT Biopharma. Atossa Genetics' average media sentiment score of 0.55 beat GT Biopharma's score of 0.00 indicating that Atossa Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GT Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atossa Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Atossa Genetics beats GT Biopharma on 11 of the 14 factors compared between the two stocks.

Get GT Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GTBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GTBP vs. The Competition

Export

Metric	GT Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$15.12M	$3.34B	$6.35B	$12.29B
Dividend Yield	N/A	2.29%	2.79%	5.33%
P/E Ratio	-0.07	18.53	21.09	25.34
Price / Sales	N/A	289.80	528.21	79.17
Price / Cash	28.03	129.82	44.13	56.16
Price / Book	2.06	6.92	10.00	7.01
Net Income	-$28.35M	$24.39M	$3.55B	$335.27M
7 Day Performance	9.93%	2.68%	1.98%	1.28%
1 Month Performance	15.93%	-1.45%	-0.88%	0.16%
1 Year Performance	-83.78%	62.18%	36.38%	34.54%

GT Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GTBP GT Biopharma	1.1711 of 5 stars	$0.43 +3.3%	N/A	-83.7%	$15.12M	N/A	N/A	8	Earnings Report Gap Down
ELUT Elutia	2.897 of 5 stars	$1.07 +1.0%	$6.00 +460.2%	-31.0%	$45.82M	$12.29M	1.31	180	Gap Down
IXHL Incannex Healthcare	0.9363 of 5 stars	$3.84 -15.3%	N/A	-46.3%	$45.76M	$90K	N/A	3	Positive News
INCR InterCure	0.4899 of 5 stars	$0.84 +1.8%	N/A	-45.6%	$45.66M	$78.47M	27.83	350	Gap Up
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	$45.46M	$35.59M	N/A	70

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GTBP) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GT Biopharma (GTBP) Competitors

GTBP vs. ELUT, IXHL, INCR, NBRV, and ATOS

How does GT Biopharma compare to Elutia?

Summary

How does GT Biopharma compare to Incannex Healthcare?

Summary

How does GT Biopharma compare to InterCure?

Summary

How does GT Biopharma compare to Nabriva Therapeutics?

Summary

How does GT Biopharma compare to Atossa Genetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTBP vs. The Competition

GT Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GT Biopharma (GTBP) Competitors

GTBP vs. ELUT, IXHL, INCR, NBRV, and ATOS

How does GT Biopharma compare to Elutia?

Which has more risk & volatility, ELUT or GTBP?

Which has better earnings and valuation, ELUT or GTBP?

Does the media favor ELUT or GTBP?

Do institutionals and insiders believe in ELUT or GTBP?

Is ELUT or GTBP more profitable?

Do analysts recommend ELUT or GTBP?

Summary

How does GT Biopharma compare to Incannex Healthcare?

Which has better valuation & earnings, IXHL or GTBP?

Is IXHL or GTBP more profitable?

Does the media favor IXHL or GTBP?

Do institutionals & insiders believe in IXHL or GTBP?

Which has more volatility and risk, IXHL or GTBP?

Do analysts rate IXHL or GTBP?

Summary

How does GT Biopharma compare to InterCure?

Which has more risk and volatility, GTBP or INCR?

Does the media prefer GTBP or INCR?

Do analysts rate GTBP or INCR?

Do insiders and institutionals have more ownership in GTBP or INCR?

Is GTBP or INCR more profitable?

Which has better earnings & valuation, GTBP or INCR?

Summary

How does GT Biopharma compare to Nabriva Therapeutics?

Do institutionals and insiders have more ownership in NBRV or GTBP?

Which has more volatility & risk, NBRV or GTBP?

Which has preferable earnings and valuation, NBRV or GTBP?

Is NBRV or GTBP more profitable?

Does the media favor NBRV or GTBP?

Do analysts recommend NBRV or GTBP?

Summary

How does GT Biopharma compare to Atossa Genetics?

Which has higher earnings and valuation, GTBP or ATOS?

Do analysts recommend GTBP or ATOS?

Which has more risk and volatility, GTBP or ATOS?

Do institutionals & insiders believe in GTBP or ATOS?

Is GTBP or ATOS more profitable?

Does the media prefer GTBP or ATOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTBP vs. The Competition

GT Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools